CureVac's Stock Market Exit Finalized Following BioNTech Acquisition - AD HOC NEWS
Litigation, Intellectual Property News
Legal Dispute Resolution Clears Path. The acquisition also concludes a protracted patent conflict between the two German mRNA pioneers. In August 2025 ...
